FTC V. Cephalon — The Actavis Fray Begins
Last year the U.S. Supreme Court in a landmark decision ruled that pharmaceutical "reverse payment" settlements in Hatch-Waxman Act "Paragraph 4" patent litigation are subject to challenge, departing from the rule...To view the full article, register now.
Already a subscriber? Click here to view full article